1 |
A. C. Porter and R. R. Vaillancourt, Tyrosine Kinase Receptor-activated Signal Transduction Pathways Which Lead to Oncogenesis, Oncogene, 17, 1343 (1998)
DOI
ScienceOn
|
2 |
P. Blume-Jensen and Tony Hunter, Oncogenic Kinase Signalling, Nature, 411, 355 (2001)
DOI
ScienceOn
|
3 |
D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oncol., 29 (Supplement 4), 37 (2002)
DOI
ScienceOn
|
4 |
Burris H. A. 3rd, Hurwitz H. I., Dees E. C., Dowlati A., Blackwell K. L., O'Neil B., Marcom P. K., Ellis M. J., Overmoyer B., Jones S. F., Harris J. L., Smith D. A., Koch K. M., Stead A., Mangum S., and Spector N. L., Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), A Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients with Metastatic Carcinomas, J Clin. Oncol., 23, 5305 (2005)
DOI
ScienceOn
|
5 |
O. Tabarrini, V. Cecchetti, A. Fravolini, G. Nocentini, A. Barzi, S. Sabatini, H. Miao, and C. Sissi, Design and Synthesis of Modified Quinolones as Antitumoral Acridones, J. Med. Chem., 42, 2136 (1999)
DOI
ScienceOn
|
6 |
P. Traxler and P. Furet, Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors, Pharmacol. Ther., 82, 195 (1999)
DOI
ScienceOn
|
7 |
R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non-Small-Cell Lung Cancer, J. Clin. Oncol., 22, 3238 (2004)
DOI
ScienceOn
|
8 |
A. Levitzki, Protein Tyrosine Kinase Inhibitors as Therapeutic Agents, Pharmacol. Ther., 82, 231 (1999)
DOI
ScienceOn
|
9 |
C. C. Price, N. J. Leonard, and D. Y. Curtin, 4-(4'-Diethylamino-1'- methylbutylamino)-7-chloroquinazoline, J. Amer. Chem. Soc. 68, 1305 (1946)
DOI
|
10 |
B. Moy, P. Kirkpatrick, S. Kar, and P. Goss, Lapatinib, Nature Rev. Drug Discov. 6, 431 (2007)
DOI
ScienceOn
|
11 |
D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambroso, J. M. Nelson, W. R. Leopold, R. W. Connors, and A. J. Bridges, A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, Science, 265, 1093 (1994)
DOI
|
12 |
R. Tibes, J. Trent, and R. Kurzrock, Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics, Ann. Rev. Pharmacol. Toxicol., January 6, 2005
|
13 |
J. Vesel, L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J.-y. Kato, L. Detkvaud, S. Leclerc, and L. Meijere, Inhibition of Cyclin-dependent Kinases by Purine Analogues, Eur. J. Biochem., 224, 771 (1994)
DOI
ScienceOn
|
14 |
E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacon, A. Ray, and D. Griffin, AMN107 (nilotinib): A Novel and Selective Inhibitor of BCR-ABL. Brit. J. Canver, 94, 1765 (2006)
DOI
ScienceOn
|
15 |
J. Parrick and R. Ragunathan, Studies of Phthalazine-5,8-quinone, A Ring Contraction, and Some Novel and Potentially Useful Fluorescent Phthalimides, J. Chem. Soc., Perkin Trans. 1, 211 (1993)
|
16 |
A. J. Bridges, H. Zhou, D. R. Cody, G. W. Rewcastle, A. McMichael, H. D. H. Showalter, D. W. Fry, A. J. Kraker, and W. A. Denny, Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4- (3-Bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor, J. Med. Chem., 39, 267 (1996)
DOI
ScienceOn
|